您的当前位置:首页 > 行业数据 > 表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率
图片属性
图片格式:PNG 图片大小:606KB 图片尺寸:2356*976
同报告图片
 / 4
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率_第1页
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
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率_第2页
fCDotYTkuqfotJ/lgLrooaggfCAyMDI0IHwgMjAyNUUgfCAyMDI2RSB8IDIwMjdFIHwKfCAtLS0gfCAtLS0gfCAtLS0gfCAtLS0gfCAtLS0gfAp8IOeOsOmHkea1gemHj+ihqCB8IDIwMjQgfCAyMDI1RSB8IDIwMjZFIHwgMjAyN0UgfAp8IOWIqea2puihqCB8IDIwMjQgfCAyMDI1RSB8IDIwMjZFIHwgMjAyN0UgfAp8IOS4u+imgei0ouWKoeavlOeOhyB8IDIwMjQgfCAyMDI1RSB8IDIwMjZFIHwgMjAyN0UgfAoK6LWE5paZ5p2l5rqQ77ya5aSp6L2v44CB5rmY6LSi6K+B5Yi456CU56m25omA
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率_第3页
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
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率_第4页
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
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率_第5页
所属报告: 康希诺-公司研究报告-创新型疫苗领先者新增长曲线未来可期-250331(33页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠